XML 34 R8.htm IDEA: XBRL DOCUMENT v3.19.3
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Operating activities    
Net loss $ (266,659) $ (270,914)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of debt discount and deferred financing 2,290 7,868
Depreciation and amortization 3,261 3,015
Stock-based compensation 31,522 20,873
Loss on exchange of convertible debt 40,624 0
Change in fair value of derivatives 0 2,739
Non-cash changes in the fair value of contingent consideration payable 2,652 2,700
Foreign currency remeasurement loss 2,665 775
Other (136) 0
Changes in operating assets and liabilities:    
Accounts receivable (12,644) (5,182)
Inventories (2,016) (2,049)
Prepaid expenses and other current assets (3,321) 2,633
Accounts payable and accrued expenses 8,714 3,684
Other non-current assets and liabilities 1,964 (420)
Deferred reimbursements (1,500) (5,000)
Net cash used in operating activities (192,584) (239,278)
Investing activities    
Sale and redemption of marketable securities 389,242 388,135
Purchases of marketable securities (311,965) (440,963)
Capital expenditures (9,087) (4,571)
Net cash provided by (used in) investing activities 68,190 (57,399)
Financing activities    
Proceeds from issuance of common stock, net of issuance costs 188,994 294,584
Proceeds from senior secured term loan 0 146,622
Payment of finance leases (177)  
Payment of finance leases   (218)
Purchase of vested restricted stock units (3,001) (2,681)
Proceeds from termination of capped call confirmations 19,875 0
Proceeds from exercise of stock options 7,808 8,492
Proceeds of exercise of warrants 812 3,617
Net cash provided by financing activities 214,311 450,416
Effect of exchange rate changes on cash, cash equivalents, and restricted cash (2,591) (1,146)
Net increase in cash, cash equivalents, and restricted cash 87,326 152,593
Cash, cash equivalents, and restricted cash at beginning of period 82,375 51,237
Cash, cash equivalents, and restricted cash at end of period 169,701 203,830
Cash paid during the period for interest    
Cash paid during the period for interest 13,145 3,787
Capital expenditures, unpaid 2,802 538
Payment of contingent consideration in shares $ 9,316 $ 0